- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Glucotrack, Inc.: Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member | 1 | GlobeNewswire (USA) | ||
| Mi | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | Glucotrack's 3-year diabetes sensor implant clears initial human safety trial | 1 | FierceBiotech | ||
| 05.02. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.02. | GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM | - | RTTNews | ||
| 04.02. | Glucotrack announces pricing of $3M public offering | 1 | Seeking Alpha | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 04.02. | Glucotrack sets terms for $3 million public stock offering | 1 | Investing.com | ||
| 04.02. | Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering | 4 | GlobeNewswire (USA) | ||
| 04.02. | Glucotrack soars on completion of first human clinical study of continuous blood glucose monitor | 2 | Seeking Alpha | ||
| 04.02. | Glucotrack completes first-in-human continuous blood glucose monitor implant study | 3 | MassDevice | ||
| 04.02. | Glucotrack reports success in first human glucose monitor trial | 5 | Investing.com | ||
| 04.02. | Glucotrack, Inc.: Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor | 118 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 30.01. | Glucotrack to execute 1-for-20 reverse stock split | 4 | Seeking Alpha | ||
| 30.01. | Glucotrack announces 1-for-20 reverse stock split | 2 | Investing.com | ||
| 30.01. | Glucotrack kündigt Aktienzusammenlegung im Verhältnis 1:20 an | 1 | Investing.com Deutsch | ||
| 30.01. | Glucotrack, Inc.: Glucotrack Announces Reverse Stock Split | 53 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization... ► Artikel lesen | |
| 29.01. | Glucotrack, Inc.: Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer | 156 | GlobeNewswire (Europe) | RUTHERFORD, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 29.01. | Glucotrack, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.01. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.01. | Glucotrack, Inc.: Glucotrack Announces ISO 13485:2016 Certification | 6 | GlobeNewswire (USA) |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 58,20 | +0,69 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler stellt Geschäftskontinuität nach Cyberangriff sicher | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Sonstiges
Eckert & Ziegler stellt Geschäftskontinuität nach Cyberangriff sicher
25.02.2025 / 09:59 CET/CEST
Für den... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,130 | -1,37 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 13.02.2025 | Das Instrument PSH0 CA81752F1062 SERNOVA BIOTHERAPEUTICS EQUITY hat seinen ersten Handelstag am 13.02.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y
The instrument PSH0 CA81752F1062... ► Artikel lesen | |
| SYNLAB | 11,360 | -0,18 % | UNGLAUBLICHE Sondermeldung bei Synlab Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
| NUGEN MEDICAL DEVICES | 0,044 | +5,26 % | Unglaubliche News! Der Super-CEO der alle Türen öffnen kann! | ||
| ATOSSA THERAPEUTICS | 0,726 | +2,98 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,272 | -7,48 % | UniDoc Health Corp.: UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis | VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), is issuing this news release to advise its shareholders that the... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,963 | -1,21 % | Ping An Healthcare and Technology Company Limited: Ping An Health Pioneers AI-Driven Healthcare with DeepSeek Integration | HONG KONG and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando | BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,022 | +17,20 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,510 | +5,81 % | Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version | ||
| CYTOSORBENTS | 1,060 | +2,71 % | CytoSorbents sichert sich 1,6 Millionen US-Dollar durch Optionsscheinausübungen | ||
| QUIDELORTHO | 38,000 | -1,55 % | QuidelOrtho Corp - 10-K, Annual Report | ||
| VERU | 0,472 | -5,33 % | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,770 | -0,32 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,331 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.
